Evaluation of Patients with Hemophilia in Nineveh Governorate

Evaluation of Hemophilia in Nineveh

Section: Research Paper
Issue
Vol. 48 No. 1 (2026): Volume 48 Issue 1
Pages
43-52

Keywords:

Hemophilia A, hemophilia B, hemarthrosis, inhibitor

Abstract

Background: Hemophilia is the most common significant hereditary bleeding disease, resulting from a deficiency in clotting factor VIII (Hemophilia A) or factor IX (Hemophilia B). Deficiency of these coagulation factors will lead to prolonged bleeding. Hemophilia A is the most common type. Hemophilia is classified according to the coagulation factor level into mild, moderate, and severe disease.


Aims: To evaluate the clinical and laboratory characteristics of patients registered with hemophilia in the Nineveh hemophilia database, focusing on a representative cohort of 100 individuals. 


Patients and methods: This study is a cross-sectional study, carried out in Nineveh governorate at Ibn-Sina Teaching Hospital and Al-Hadbaa Specialized Hospital between January and October 2025. As of 2025, there are 305 patients registered with hemophilia in Nineveh governorate, according to the National Hemophilia Registry. From this population, a cohort of 100 patients was recruited for detailed clinical and laboratory analysis. These patients underwent investigations that encompassed: complete blood count, coagulation study, which includes prothrombin time (PT), activated partial thromboplastin time (APTT), mixing study, factor assay, and Bethesda assay in addition to viral screen.


Results: Among the 100 hemophilia patients, hemophilia A patients form the majority (95%). The mean age (±SD) of enrolled patients was 14.74 (± 11.914) years.  The first clinical presentation is bleeding, mostly after circumcision, while hemarthrosis was the most commonly encountered presentation throughout the course of the disease. The association between clinical characteristics and disease severity shows a significant statistical difference concerning the gum bleeding (P-value=0.018) and epistaxis (P-value=0.020). Patients having positive inhibitors form 15% of enrolled patients.


Conclusion: Our findings highlight a high prevalence of moderate hemophilia and joint morbidity in Nineveh, necessitating a dual strategy of standardized neonatal screening and home-infusion programs to bridge the gap between clinical intent and functional outcomes.

References

  1. Zimmerman B, Valentino LA. Hemophilia: in review. Pediatr Rev. 2013 Jul;34(7):289–95. Doi: https://doi.org/10.1542/pir.34-7-289
  2. Berntorp E, Fischer K, Hart DP, Mancuso ME, Stephensen D, Shapiro AD, et al. Haemophilia. Nat Rev Dis Primers. 2021;7(1):45. Doi: https://doi.org/10.1038/s41572-021-00278-x.
  3. World Federation of Hemophilia. What is hemophilia? [Internet]. Montreal: WFH; 2012. Available from: https://www.wfh.org
  4. Tanaka KA, Terada R, Butt AL, Mazzeffi MA, McNeil JS. Factor VIII: a dynamic modulator of hemostasis and thrombosis in trauma. Anesth Analg. 2023;136(5):894–904. Doi: https://doi.org/10.1213/ane.0000000000006356.
  5. Mazurkiewicz-Pisarek A, Płucienniczak G, Ciach T, Płucienniczak A. The factor VIII protein and its function. Acta Biochim Pol. 2016;63(1):11–6. Doi: https://doi.org/10.18388/abp.2015_1056.
  6. Bannow BS, Recht M, Négrier C, Hermans C, Berntorp E, Eichler H, et al. Factor VIII: long-established role in haemophilia A and emerging evidence beyond haemostasis. Blood Rev. 2019;35:43–50. Doi: https://doi.org/10.1016/j.blre.2019.03.002
  7. Mansouritorghabeh H. Clinical and laboratory approaches to hemophilia A. Iran J Med Sci. 2015;40(3):194–200. https://pmc.ncbi.nlm.nih.gov/articles/PMC4430880/
  8. Alhaosawi MM. Target joint: new concept of identification. J Appl Hematol. 2015;6(1):35–38. Available from: 1. https://journals.lww.com/jaht/fulltext/2015/06010/target_joint__new_concept_of_identification_.8.aspx
  9. Jardim LL, Chaves DG, Rezende SM. Development of inhibitors in hemophilia A: an illustrated review. Res Pract Thromb Haemost. 2020 Jul;4(5):752–60. Doi: https://doi.org/10.1002/rth2.12335
  10. Favaloro EJ, Gosselin RC, Pasalic L, Lippi G. Hemostasis and thrombosis: an overview focusing on associated laboratory testing to diagnose and help manage related disorders. Methods Mol Biol. 2023;2663:3-48. Doi: https://doi.org/10.1007/978-1-0716-3175-1_1
  11. Lippi G, Meschi T, Borghi L. Variation of activated partial thromboplastin time according to age and sex in a large population study: analytical and clinical implications. Blood Coagul Fibrinolysis. 2012;23(2):177–8. Doi: https://doi.org/10.1097/mbc.0b013e32834ee0fb
  12. Srivastava A, Santagostino E, Dougall A, Kitchen S, Sutherland M, Pipe SW, et al. WFH guidelines for the management of hemophilia. Haemophilia. 2020;26:1–158. Doi: https://doi.org/10.1111/hae.14046
  13. Manco-Johnson MJ, Abshire TC, Shapiro AD, Riske B, Hacker MR, Kilcoyne R, et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med. 2007 Aug;357(6):535–44. Doi: https://doi.org/10.1056/nejmoa067659
  14. Weyand AC, Pipe SW. New therapies for hemophilia. Blood. 2019 Jan;133(5):389–98. Doi: https://doi.org/10.1182/blood-2018-08-872291
  15. Astermark J, Donfield SM, DiMichele DM, Gringeri A, Gilbert SA, Waters J, et al. A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study. Blood. 2007 Jan;109(2):546–51. Doi: https://doi.org/10.1182/blood-2006-04-017988.
  16. Oomen I, Camelo RM, Rezende SM, Voorberg J, Mancuso ME, Oldenburg J, et al. Determinants of successful immune tolerance induction in hemophilia A: systematic review and meta-analysis. Res Pract Thromb Haemost. 2023 Jan;7(1):100020. Doi: https://doi.org/10.1016/j.rpth.2022.100020
  17. Young G, Callaghan M, Dunn A, Kruse-Jarres R, Pipe S. Emicizumab for hemophilia A with factor VIII inhibitors. Expert Rev Hematol. 2018 Nov;11(11):835–46. Doi: https://doi.org/10.1080/17474086.2018.1531701.
  18. Kadhim KAR, Al-Lami FH, Baldawi KH. Epidemiological Profile of Hemophilia in Baghdad-Iraq. INQUIRY: The Journal of Health Care Organization, Provision, and Financing. 2019;56. Doi: https://doi.org/10.1177/0046958019845280
  19. Abood GM, Dehiol RK, Mones HM. Prevalence of Hemophilia and Clinicodemographic Characteristics of Hemophilic Patients Aged ≤ 18 Years in Thi-Qar, Iraq. Global Pediatric Health. 2024;11. Doi: https://doi.org/10.1177/2333794x241280119
  20. Qasim Z, Naseem L, Asif N, Hassan K. Haemophilia; Pattern of Clinical Presentation and Disease Severity. Int J Pathol. 2013;11(2):58-63. Available from: https://www.jpathology.com/index.php/OJS/article/view/141
  21. Owaidah T, Al Momen A, Alzahrani H, Almusa A, Alkasim F, Tarawah A, et al. The prevalence of factor VIII and IX inhibitors among Saudi patients with hemophilia: Results from the Saudi national hemophilia screening program. Medicine 2017;96(2):e5456. Doi: https://doi.org/10.1097/md.0000000000005456
  22. Ali IM, Hussein AA, Al-Musawi IM, Hillawi SS, Kadhim NS, Jasim AA. Epidemiological profile of hemophilia A in Karbala-Iraq. J Med Life. 2023 Nov;16(11):1611. Doi: https://doi.org/10.25122/jml-2023-0218.
  23. Abdulrahman HJ, Eissa AA. Health-related quality of life among hemophilic adult patients from Iraq/Duhok. Iraq J Hematol. 2022 Jan;11(1):38–44. Doi: https://doi.org/10.4103/ijh.ijh_48_21
  24. Alsaad O, Mohsin AM. Demography, annual incidence, and risk factors of inhibitors for pediatric hemophilia A in Basra Center for Hereditary Blood Diseases. Iraq Natl J Med. 2025 Jan;7(1):140–5. Available from: https://www.iqnjm.com/index.php/homepage/article/view/235
  25. Karaman K, Akbayram S, Garipardıç M, Öner AF. Diagnostic evaluation of our patients with hemophilia A: 17-year experience. Turk Arch Pediatr. 2015 Jun;50(2):96. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC4523992/
  26. Shamoon RP. Magnitude of arthropathy in patients with hemophilia: a single-center experience. Iraq J Hematol. 2017 Jul;6(2):78–83. Doi: https://doi.org/10.4103/ijh.ijh_24_17
  27. Lateef IA, Hamood HJ, Khaleel OA. Spectrum of hemophilia in Diyala-Iraq. Diyala J Med. 2016;10(1):53–8. Available from: https://www.djm.uodiyala.edu.iq/index.php/djm/article/view/273/196
  28. Wang J, Li Q, Cheng Y, Wang A, Qiao C, Shao J, et al. Investigation of a hemophilia family with one female hemophilia A patient and 12 male hemophilia A patients. Ann Hematol. 2025 Jan;104(1):163–70. Doi: https://doi.org/10.1007/s00277-024-06158-0.
  29. Al-Zubaidy AM. Descriptive study of hemophilia in Al-Ramadi City. Diyala J Med. 2014;6(1):55–9. Available from: https://djm.uodiyala.edu.iq/index.php/djm/article/view/365/272
  30. Kendre G, Hilalpure S, Mantri S, Goyanka S, Prince L. The target joint in severe hemophilia A. Pediatr Oncall J. 2020 Feb;17(1):30–1. Doi: https://doi.org/10.7199/ped.oncall.2020.2
  31. Rasheed NS, Eissa AA. Molecular characterization of hemophilia A patients in Duhok, Iraq. Pharmacophore. 2023;14(6-2023):20–7. Doi: https://doi.org/10.51847/YerIDDpIcm
  32. Bawazir OA, Alharbi I. Circumcision in hemophilia: a multicenter experience. J Pediatr Hematol Oncol. 2021 Jan;43(1):e33–6. Doi: https://doi.org/10.1097/mph.0000000000001960
  33. Payal V, Sharma P, Goyal V, Jora R, Parakh M, Payal D. Clinical profile of hemophilia patients in Jodhpur Region. Asian J Transfus Sci. 2016 Jan;10(1):101–4. Doi: https://doi.org/10.4103/0973-6247.164269
  34. Islam MN, Biswas AR, Nazneen H, Chowdhury N, Alam M, Banik J, et al. Clinical profile and demographic characteristics of moderate and severe hemophilia patients in a tertiary care hospital of Bangladesh. Orphanet J Rare Dis. 2022 Jul;17(1):254. Doi: https://doi.org/10.1186/s13023-022-02413-7.
  35. Abdel Ghany HM, Hassab HM, El-Noueam KI. Hemophilic arthropathy: clinical, radiologic, and functional evaluation: a single-center experience in a limited resource country. Egypt Rheumatol Rehabil. 2016 Jan;43(1):35–40. Doi: https://doi.org/10.4103/1110-161X.177425
  36. Singh A, Rawat S, Kushwaha R, Jain M, Verma SP, Singh US. Clinicopathological parameters of haemophilia patients at a tertiary care centre in northern India. Cureus. 2023 Jul;15(7). Doi: https://doi.org/10.7759/cureus.41670
  37. Peng HM, Wang LC, Zhai JL, Weng XS, Feng B, Wang W. Transfusion-transmitted infections in hemophilia patients who underwent surgical treatment: a study from a single center in north China. Arch Med Sci. 2020 Feb 26;16(1):97–103. Doi: https://doi.org/10.5114/aoms.2020.92892
  38. World Federation of Hemophilia. Report on the Annual Global Survey 2023. Montreal, Canada: WFH; 2024. Available from: https://www1.wfh.org/publications/files/pdf-2525.pdf
  39. World Federation of Hemophilia. Report on the Annual Global Survey 2016 [Internet]. Montreal: World Federation of Hemophilia; 2016. Available from: https://www1.wfh.org/publication/files/pdf-1690.pdf.
  40. Schrijvers LH, Kars MC, Beijlevelt‐van der Zande M, Peters M, Schuurmans MJ, Fischer K. Unravelling adherence to prophylaxis in haemophilia: a patients’ perspective. Haemophilia. 2015 Sep;21(5):612–21. Doi: https://doi.org/10.1111/hae.12660

Authors

Zainab Saud Abdulazeez

Nineveh Health Directorate

Muna Abdulbasit Kashmoola

Identifiers

DOI: 10.33899/acmm.v48.i1.60338

Download this PDF file
PDF

Statistics

How to Cite

1.
Evaluation of Patients with Hemophilia in Nineveh Governorate: Evaluation of Hemophilia in Nineveh. Ann. coll. Med. Mosul [Internet]. 2026 Jun. 30 [cited 2026 Jul. 18];48(1):43-52. Available from: https://mmed.uomosul.edu.iq/index.php/mmed/article/view/60338

Author Biography

Muna Abdulbasit Kashmoola

Department of Pathology, College of Medicine

How to Cite

1.
Evaluation of Patients with Hemophilia in Nineveh Governorate: Evaluation of Hemophilia in Nineveh. Ann. coll. Med. Mosul [Internet]. 2026 Jun. 30 [cited 2026 Jul. 18];48(1):43-52. Available from: https://mmed.uomosul.edu.iq/index.php/mmed/article/view/60338